The Greater China Region Oncology Drug Development Landscape 2025 – OmicsX

Drug Development Landscape

ONCOLOGY

GREATER CHINA REGION

Drug Development Landscape

ONCOLOGY

GREATER CHINA REGION

Drug Development Landscape

ONCOLOGY

GREATER CHINA REGION

INTELLIGENCE

REPORT

First

Schedule Release in October 2024

In The Greater China Region

Drug Discovery Companies

To Cover 450+Active Oncology

635 Oncology
Drug Discovery
Companies
In 24 European
Countries.

Buy Now

Table of Contents

First of its kind Report to provide Complete Landscape on Oncology Drug Discovery in Europe Region.

Largest Coverage on Oncology Drug Developers in Europe.
Developed through Years of Dedicated Team Work.
Economic & User Friendly Option in compare with any other similar available market solution.
Complete free after sales Support, including regular intelligence updates.

The Europe’s Oncology Drug Development Landscape Market Intelligence Report is designed to Quickly Identify Active Oncology Drug Developers in the region, with their Drug Pipeline, Technologies, Management Expertise, Funding and Partnering capabilities.

Report covers the Largest set of Active Oncology Drug Developers in European Region; with their current late/early stage molecules available for partnering and thus stands out as a perfect market insights partnering and business development tool.

largest coverage Guranteed

providing intelligence at fingertips

Countries

24 European Countries’ Covered

Drug developers

Oncology Drug Developers Insights

Molecules in Development

200

Individual Drug Mechanism of Action & Drug Target

Cancer Targets

Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies

Prebuild Intelligence

identify Emerging Technologies and Molecules

Molecule Type	The Report Highlights Active Drug Developers Developing
Cellular Therapeutics	*89 European Cancer Drug Discovery Companies Developing – CAR-T / CAR-NK & other Cell based Therapies Targeting Cancer.* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Monoclonal Antibodies	*96 European Cancer Drug Discovery Companies Developing Monoclonal Antibodies against Tumor Antigens.* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Bispecific Antibodies & Bispecific T Cell Engagers	*42 European Cancer Drug Discovery Companies Developing Bispecific Antibodies & Bispecific T Cell Engagers.* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Antibody Drug Conjugates	*42 European Cancer Drug Discovery Companies Developing Antibody Drug Conjugates targeting Cancer.* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Cancer Vaccines	*65 European Cancer Drug Discovery Companies Developing Vaccines against Cancer.* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Kinase Inhibitors	*61 European Cancer Drug Discovery Companies Developing Small Molecule Kinase Inhibitors Targeting Cancer* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Targeted Protein Degraders	*22 European Cancer Drug Discovery Companies Developing Small Molecule Targeted Protein Degraders against Cancer* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Cancer Targeting Radiopharmaceuticals	*22 European Cancer Drug Discovery Companies Developing Cancer Targeting Radiopharmaceuticals.* (Complete Insights covering Companies, Technologies, Deals, Funding & Molecules in Development)
Oncolytic Viruses	*26 European Cancer Drug Discovery Companies Developing Oncolytic Viruses Based Cancer Targeting Drugs.* (Intelligence covering Companies, Technologies & Molecules in Development)
Microbiome & Engineered Bacteria	*17 European Cancer Drug Discovery Companies Developing Microbiome & Engineered Bacteria Based Cancer Targeting Drugs* (Intelligence covering Companies, Technologies & Molecules in Development)

intelligence supercharged

956 pages full of Insights

Knowledge Multiplier

Better Than Others

Comparisons	Europe Oncology Drug Development Landscape 2024	Other Intelligence Sources
Active Oncology Drug Developers	635 Active Companies (Well Funded with clear defined clinical & early stage Pipeline)	250-350 Companies (with many inactive and other domain companies)
Oncology Drugs in Development	1000+ Onco Targeting Drugs in Active Development (Complete Clinical & Preclinical Pipeline with indications, Drug Targets and Mechanism of Action)	400 – 600 Cancer Targeting Drugs (mainly focuses on Clinical Stage molecules)
Bio-Partnering Details	800+ Oncology Deals complete details. (Complete coverage on Oncology focused Deals, Funding & Partnering Activities, since company’s incorporation)	Limited to Database / Resource Subscribed to. (Also it may require mapping of events between two or more different resources and filtering Onco Linked Deals).
Single Step Connect	Over 1500+ Key Decision Makers in 635 Companies with valid emails and LinkedIn Accounts Links for one click contact. (Further CRMS Development Support is also available)	No Customized Solution Available in Market (Needs months of hard team work to prepare authentic business development tool.